Network Meta-analysis of Chinese patent medicine containing Hirudo in treatment of atherosclerosis.
10.19540/j.cnki.cjcmm.20221018.501
- Author:
Qian-Qian HAN
1
;
Zi-Yun WEN
1
;
Qing LYU
1
;
Yun-Yun PAN
2
Author Information
1. Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University Guangzhou 510515, China the First Affiliated Hospital of Guangdong Pharmaceutical University Guangzhou 510080, China.
2. Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University Guangzhou 510515, China.
- Publication Type:Journal Article
- Keywords:
Bayesian model;
Chinese patent medicine;
Hirudo;
atherosclerosis;
network Meta-analysis
- MeSH:
Humans;
Network Meta-Analysis;
Nonprescription Drugs/therapeutic use*;
Capsules;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Bayes Theorem;
Carotid Intima-Media Thickness;
Drugs, Chinese Herbal/therapeutic use*;
Atherosclerosis/drug therapy*;
Medicine, Chinese Traditional
- From:
China Journal of Chinese Materia Medica
2023;48(1):234-246
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to evaluate the efficacy and safety of Chinese patent medicines containing Hirudo in the treatment of atherosclerosis(AS) by network Meta-analysis, and to provide evidence-based reference for clinical treatment of AS. The clinical randomized controlled trial(RCT) on the treatment of atherosclerosis with Chinese patent medicines containing Hirudo were searched in CNKI, Wanfang, VIP, SinoMed, PubMed and EMbase from the establishment of the databases to July 1, 2022. And data extraction and quality assessment of the included RCT was performed according to the Cochrane standards. Stata 17 and ADDIS 1.16.5 were then used for Bayesian model network Meta-analysis. Finally, 67 RCTs with a total sample size of 6 826 cases were included, 3 569 cases in the experimental group and 3 257 cases in the control group, involving three oral Chinese patent medicines. Network Meta-analysis showed that in terms of reducing intima-media thickness(IMT), the top three Chinese patent medicines were Tongxinluo Capsules+sta-tins>Maixuekang Capsules+statins>Maixuekang Capsules. In terms of reducing plaque area, the top one was Maixuekang Capsules+sta-tins, and the other Chinese patent medicines had similar efficacy. For lowering AS Crouse scores, the top three were Maixuekang Capsules>Tongxinluo Capsules+statins>Naoxintong Capsules. For decreasing plaque number, the top three were Naoxintong Capsules+sta-tins>Tongxinluo Capsules+statins>Tongxinluo Capsules. With regard to adverse reactions/events, Naoxintong Capsules+statins had the lo-west incidence. In conclusion, in Chinese patent medicines containing Hirudo for the treatment of AS, Tongxinluo Capsules+statins, Maixuekang Capsules, Maixuekang Capsules+statins, and Naoxintong Capsules+statins were the primary choices to reduce IMT, AS Crouse scores, plaque area, and plaque number, respectively. The efficacy of Chinese patent medicines containing Hirudo with or without statins was more significant than that of statins alone in the four outcome indexes. Additionally, the treatment of AS should be evaluated comprehensively, and attention should be paid to Chinese patent medicines or their combination with western medicine, to optimize the treatment effect and minimize adverse reactions as the benchmark.
